Is Compounded Semaglutide Still Legal
in March 2026? The Honest Answer.

Few regulatory questions in healthcare have generated more confusion — and more misinformation — than the legal status of compounded semaglutide and tirzepatide. On one side, telehealth providers continue marketing these products aggressively. On the other, some media headlines have declared compounded GLP-1s effectively dead. The truth, as of March 2026, is more nuanced than either camp suggests.

Understanding the real legal landscape matters for two reasons. First, for patients: knowing you're working within a legal framework protects you from receiving substandard or fraudulently marketed products. Second, for your wallet: providers operating outside the legal framework may be cutting corners that affect your health.

This analysis is based on FDA guidance documents, federal court rulings through early 2026, and expert pharmacy law analysis. It is not legal advice — regulatory situations evolve, and individual circumstances vary.

The Timeline That Got Us Here

The 503A vs. 503B Distinction — Why It Matters More Than Ever

Understanding the difference between 503A and 503B pharmacies is essential to understanding the current legal landscape.

503B Outsourcing Facilities — More Restricted

503B facilities are FDA-registered outsourcing facilities that can produce large batches of medication for healthcare providers without patient-specific prescriptions. They previously used the shortage exception to bulk-compound semaglutide and tirzepatide. With both shortages resolved, 503B facilities can no longer legally produce these medications in bulk using the shortage exception. Some 503B facilities have pivoted to compounding formulations with documented clinical differences (e.g., different inactive ingredients, different delivery mechanisms) — but this is a narrower pathway with stricter requirements.

503A Compounding Pharmacies — More Available, With Conditions

503A pharmacies compound medications for individual patients based on valid prescriptions. They are regulated primarily by state pharmacy boards. Under 503A, a compounding pharmacy can compound a commercially available drug (like semaglutide) when the prescribing practitioner documents a clinical difference — a legitimate patient-specific reason why the commercially available product won't work.

The clinical difference pathway is real and well-established in pharmacy law. Valid examples include: a patient who needs a lower starting dose not commercially available (the lowest commercially available semaglutide dose is 0.25mg/week, but some patients benefit from starting at 0.1mg or 0.15mg), a patient with allergies to inactive ingredients in the commercial product, or a patient who cannot use a pen device and requires a different delivery format.

The key requirement: the prescribing physician must actually document this clinical difference in the prescription. It can't be boilerplate. It should reflect the individual patient's clinical situation.

What This Means for Patients Right Now

Here's the practical reality for patients in March 2026:

The "Clinical Difference" Requirement — What Providers Are Actually Doing

The clinical differentiation pathway is the central legal mechanism enabling 503A compounding of semaglutide in March 2026. In practice, compliant telehealth providers are documenting clinical differences such as:

• Non-standard starting doses: Some patients genuinely benefit from starting at doses lower than 0.25mg/week — particularly those with significant GI sensitivity or low body weight. These doses aren't commercially available.
• Inactive ingredient considerations: Some patients have intolerances to excipients in the commercial products (Ozempic contains benzyl alcohol as a preservative, for example). A compounded version without benzyl alcohol is a legitimate clinical difference for a patient with documented sensitivity.
• Combination formulations: Some providers use compounded formulations that combine semaglutide with vitamins (B12), anti-nausea agents, or other components. These combination products are technically distinct from the commercial product.
• Delivery format differences: Compounded vials with insulin syringes allow dose titration flexibility that pre-filled pens don't. For patients needing precise micro-dose adjustments, this is a documented clinical difference.

The legal question is whether these clinical differences are genuine and documented, or whether they're boilerplate language added to paperwork to technically comply with the requirement. Legitimate providers ensure each prescription has individualized documentation. Providers cutting corners may use template language that doesn't reflect actual patient-specific need.

The Court Cases Reshaping the Landscape

Several federal court cases have challenged FDA's post-shortage enforcement actions. In one notable case, a federal district court issued a temporary restraining order preventing FDA from enforcing its restriction on 503A compounding of semaglutide, finding that FDA had not followed proper Administrative Procedure Act rulemaking requirements before implementing the restriction.

As of March 2026, the final resolution of these cases remains pending, and the legal uncertainty has created a situation where compounded semaglutide availability varies somewhat by provider and jurisdiction. This is part of why working with a provider that has active legal compliance monitoring is important — the landscape is changing faster than most people can track.

Tirzepatide: A Slightly Different Picture

Compounded tirzepatide is available through 503A pharmacies under the same clinical differentiation framework as semaglutide. However, because tirzepatide's shortage was resolved earlier (October 2024 vs. February 2025 for semaglutide), the enforcement history for tirzepatide is somewhat longer, and FDA's position on tirzepatide compounding restrictions is slightly more developed.

Eli Lilly (manufacturer of Mounjaro and Zepbound) has been more aggressive in pursuing trademark and intellectual property claims against compounders using the tirzepatide name alongside their trademarks. This has led some providers to use the generic drug name more carefully in their marketing. This trademark activity does not affect the legal status of the compounded drug itself — tirzepatide is a generic drug name — but it affects how providers market their products.

How to Protect Yourself as a Patient

The most important thing you can do is work with a provider operating transparently within the current legal framework. Specifically:

• Ask for the pharmacy name and look it up. Any provider should readily give you the full name and NABP license number of the compounding pharmacy they use. You can verify this pharmacy at LegitScript.com and through your state pharmacy board.
• Ask how the clinical difference is documented for your prescription. A compliant provider should be able to explain what clinical differentiator is documented in your prescription file.
• Avoid providers who send blanket emails saying "nothing has changed." The regulatory landscape has unambiguously changed. Any provider claiming everything is identical to 2023 is not being transparent.
• Be skeptical of dramatically low prices. Cutting corners on compliance is one way providers reduce costs. If a price seems impossibly low, it's worth asking how they're achieving it.

The Bottom Line for March 2026

Compounded semaglutide and tirzepatide remain legally available to patients who work with compliant providers. The era of unrestricted bulk compounding under the shortage exception has ended. What remains is a smaller, more carefully regulated market of 503A pharmacies operating under the clinical differentiation pathway — supported, in part, by ongoing court proceedings that have limited FDA's ability to fully enforce its preferred post-shortage restrictions.

For patients who want to access these medications affordably and legally, the answer is: choose a provider carefully, ask the right questions, and verify independently. The providers we feature at GLP-1 Compound Pharmacy are operating within this current framework.